Skip to main content

Remote Job Finders (RJF)

Biotech IPOs approach ‘escape velocity’ barring yellow flags that could threaten rebound

Twenty-five biotechs have used the IPO route to go public this year—with five of those debuts occurring this month alone. It’s the most IPOs since 2021, when the industry recorded 78 during the height of the COVID-19 pandemic.

Lilly takes oral obesity race abroad with UK launch of Foundayo

Eli Lilly’s best play for Foundayo is to bring it overseas, a more price-sensitive market where the pharma can more readily outcompete Novo Nordisk “given the high margins of a small-molecule therapy,” Truist analyst Srikripa Devarakonda told BioSpace.
Scroll to top